Suppr超能文献

CC趋化因子MIP-3α在肝细胞癌中的表达增强及其临床意义

Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma.

作者信息

Rubie C, Frick V O, Wagner M, Rau B, Weber C, Kruse B, Kempf K, Tilton B, König J, Schilling M

机构信息

Department of General-, Visceral-, Vascular- and Paediatric Surgery, University of the Saarland, Homburg/Saar, Germany.

出版信息

Scand J Immunol. 2006 Jun;63(6):468-77. doi: 10.1111/j.1365-3083.2006.001766.x.

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent visceral neoplasms worldwide. Using RT-PCR, ELISA, microdissection and immunohistochemistry, we investigated the expression profiles of CCL19, CCL20, CCL21 and CXCL12 and their receptors in tumourous and tumour neighbouring tissues from patients with HCC and in nonmalignant liver lesions, respectively. All chemokines were found to be expressed in normal liver and HCC tissues, yet CCL20 was the only chemokine showing significant upregulation in HCC tissues. Clinicopathological analysis revealed a distinct increase in CCL20 expression rates in HCC tissues of grade III tumours in comparison to HCC tissues from grade II tumours. On mRNA level, only chemokine receptor CCR6 revealed significant upregulation in HCC tissues. However, immunohistochemical studies indicated a marked CCR6 expression accumulated in a streak of normal cells along the tumour invasion front in all our HCC specimens which could provide a stimulative signal for the tumour to further expand. The present findings show significant overexpression of CCL20 in the tumour tissues and marked overexpression of the corresponding receptor CCR6 in the tumour invasion front of HCC patients in comparison to normal liver. Moreover, CCL20 expression was found to correlate with tumour grade and therefore, we suggest that the CCL20/CCR6 system may be involved in hepatocarcinogenesis.

摘要

肝细胞癌(HCC)是全球最常见的内脏肿瘤之一。我们分别使用逆转录聚合酶链反应(RT-PCR)、酶联免疫吸附测定(ELISA)、显微切割和免疫组织化学方法,研究了CCL19、CCL20、CCL21和CXCL12及其受体在肝癌患者肿瘤组织及肿瘤邻近组织以及非恶性肝损伤组织中的表达谱。结果发现所有趋化因子在正常肝脏和肝癌组织中均有表达,但CCL20是唯一在肝癌组织中显著上调的趋化因子。临床病理分析显示,与II级肿瘤的肝癌组织相比,III级肿瘤的肝癌组织中CCL20表达率明显升高。在mRNA水平上,只有趋化因子受体CCR6在肝癌组织中显著上调。然而,免疫组织化学研究表明,在我们所有的肝癌标本中,CCR6表达明显积聚在肿瘤侵袭前沿的一条正常细胞带中,这可能为肿瘤进一步扩展提供刺激信号。目前的研究结果表明,与正常肝脏相比,肝癌患者肿瘤组织中CCL20显著过表达,肿瘤侵袭前沿相应受体CCR6明显过表达。此外,发现CCL20表达与肿瘤分级相关,因此,我们认为CCL20/CCR6系统可能参与肝癌发生。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验